Radical enhancements for cognition or longevity will likely be adopted by healthy people only after they are first developed and FDA-approved as therapies for specific diseases, like Alzheimer's. Competitive pressures will then drive widespread use, similar to obesity drugs.

For early-stage MedTech startups, key milestones for investors are not just regulatory successes. They are fundamental proofs of concept—showing the device works in a model and demonstrating how it would function in a clinical setting. This builds an investor's vision of the product's future.

The sci-fi allure of brain implants and embedded chips often overshadows practical alternatives. Ariel Poler argues that most desired functionalities, from interfacing with AI to carrying identification, can be achieved with less invasive external devices like advanced hearables or wearables, questioning the necessity of risky surgical augmentation for healthy individuals.

The company's AI doesn't try to precisely decode the brain's original signals for specific finger movements. Instead, it's trained to correlate broader brain activity patterns with the user's general intent to grip, making the system more robust and adaptable.

Paradromics' founder notes that while the FDA is collaborative, the slower, understaffed CMS, which determines reimbursement for Medicare/Medicaid patients, is the primary bottleneck. Gaining its approval is critical for market access, as private insurers often follow its lead.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

Beyond the technology, Epia Neuro's strategy focuses on "surgical scalability." The implant procedure is designed to be under an hour, minimally invasive (not piercing the dura), and performable by many neurosurgeons, avoiding the bottleneck of requiring specialized centers for adoption.

The company first targets patients with disabilities, a clear medical need. By restoring functions like speech, they create platforms for enhanced abilities (e.g., prompting AI with thoughts), paving the way for a wider consumer market where the risk-benefit calculation shifts over time.

The core technology of detecting "intent" is viewed as a platform. Once the implant is in place for stroke recovery, it can be trained to detect cognitive lapses and provide real-time prompts, creating a system to assist with conditions like dementia or MCI.